Opexa Therapeutics (OPXA) +305% premarket on news it could be awarded up to $225M in a commercialization deal struck with Merck Serono for its multiple sclerosis therapy Tcelna. OPXA's lead product candidate is in Phase IIb trials in patients with secondary progressive MS, and has received FDA fast-track designation. Serono gains global development and commercial rights to Tcelna.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs